| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 269,744 | |||
| Marketable securities | 44,735 | |||
| Prepaid expenses and other current assets | 1,922 | |||
| Total current assets | 316,401 | |||
| Operating lease right-of-use assets, net | 2,198 | |||
| Property and equipment | 1,972 | |||
| Less accumulated depreciation | 337 | |||
| Property and equipment, net | 1,635 | |||
| Restricted cash | 512 | |||
| Total assets | 320,746 | |||
| Accounts payable | 2,590 | |||
| Accrued expenses | 3,327 | |||
| Operating lease liability, current | 730 | |||
| Total current liabilities | 6,647 | |||
| Derivative liability - warrants | 942 | |||
| Operating lease liability, noncurrent | 2,936 | |||
| Total liabilities | 10,525 | |||
| Preferred stock , value-Series Seed Preferred Stock | 0 | |||
| Preferred stock , value-Series APreferred Stock | 0 | |||
| Preferred stock , value-Series BPreferred Stock | 0 | |||
| Preferred stock , value-Series CPreferred Stock | 0 | |||
| Common stock, 0.0001 par value, 500,000,000 and 105,000,000 shares authorized, 25,299,102 and 251,655 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 3 | |||
| Additional paid-in capital | 428,327 | |||
| Accumulated deficit | -118,056 | |||
| Accumulated other comprehensive (loss) income | -53 | |||
| Equity, attributable to parent, total | 310,221 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 320,746 | |||
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)